Neurocrine Biosciences, Inc.

LSE:0K6R Stock Report

Market Cap: US$11.7b

Neurocrine Biosciences Balance Sheet Health

Financial Health criteria checks 6/6

Neurocrine Biosciences has a total shareholder equity of $2.5B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $3.3B and $795.8M respectively. Neurocrine Biosciences's EBIT is $544.7M making its interest coverage ratio -6.9. It has cash and short-term investments of $1.0B.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ratio-6.9x
CashUS$1.04b
EquityUS$2.51b
Total liabilitiesUS$795.80m
Total assetsUS$3.31b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 0K6R's short term assets ($1.7B) exceed its short term liabilities ($398.5M).

Long Term Liabilities: 0K6R's short term assets ($1.7B) exceed its long term liabilities ($397.3M).


Debt to Equity History and Analysis

Debt Level: 0K6R is debt free.

Reducing Debt: 0K6R has no debt compared to 5 years ago when its debt to equity ratio was 82.4%.

Debt Coverage: 0K6R has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 0K6R has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies